Pfizer's $11.63 Billion Trading Day Sees Stock Dip 0.12% Amid Eliquis Affordability Push

On July 17, 2025, Pfizer's trading volume reached $11.63 billion, ranking 80th in the day's stock market. Pfizer's stock price decreased by 0.12%.

Pfizer, in collaboration with Bristol Myers Squibb, announced a significant move to enhance patient access to their blood thinner Eliquis. Starting September 8, eligible U.S. patients with a prescription can purchase Eliquis directly through the Eliquis 360 Support program. This initiative aims to make the medication more affordable by offering a 40% discount, reducing the monthly cost from $606 to $346.

This direct-to-patient program is part of a broader effort to increase affordability and accessibility for patients. Christopher Boerner, CEO of Bristol-Myers Squibb, emphasized the commitment to improving patient access and affordability. The program will also provide copay assistance, further easing the financial burden on patients.